Sarepta Therapeutics (SRPT) Receivables - Other (2011 - 2026)

Sarepta Therapeutics has reported Receivables - Other for 16 years, with the latest figure at $136.4 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Other rose 147.1% year-over-year to $136.4 million; the trailing twelve-month figure through Mar 2026 stood at $136.4 million (up 147.1% YoY), and the FY2025 full-year result was $104.1 million, up 200.87% from the prior year.
• Receivables - Other for Q1 2026 stood at $136.4 million, up from $104.1 million in the prior quarter.
• The five-year high for Receivables - Other was $136.4 million in Q1 2026, with the low at $3.3 million in Q4 2022.
• Average Receivables - Other over 5 years is $51.4 million, with a median of $34.6 million recorded in 2024.
• Year-over-year, Receivables - Other surged 41287.5% in 2022 and tumbled 51.45% in 2024.
• Tracing SRPT's Receivables - Other over 5 years: stood at $3.3 million in 2022, then soared by 800.03% to $29.8 million in 2023, then advanced by 16.11% to $34.6 million in 2024, then surged by 200.87% to $104.1 million in 2025, then soared by 31.03% to $136.4 million in 2026.
• The last three Receivables - Other figures came in at $136.4 million (Q1 2026), $104.1 million (Q4 2025), and $128.7 million (Q3 2025), per Business Quant data.

Peer Comparison